CLYMClimb Bio Inc
$10.86+558% 1Y
$10.86
$1.6452 weeks$17.83
Price
+558%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 2% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for CLYM today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$621.9M
1 year+558%
5 years-40%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 3, 2026Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy.Regulation FD disclosure · press release
- Aug 14, 2026Climb Bio, Inc. Date: August 14, 2026 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer.Other event · Form 8-K
- Aug 6, 2026Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.